Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway

Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24

(2012) F. Wang et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

(2011) Kenneth Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy

(2010) C. Johansen et al.   BRITISH JOURNAL OF DERMATOLOGY

Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis

(2009) Erin G. Harper et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis

(2009) Shinji Kagami et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt

(2008) Nicolas Manel et al.   NATURE IMMUNOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS